Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin-induced thrombocytopenia: pathophysiology

M R Kibbe1, R Y Rhee

  • 1Department of Surgery, University of Pittsburgh, Medical Center, PA 15213, USA.

Seminars in Vascular Surgery
|December 1, 1996
PubMed
Summary

Heparin-induced thrombocytopenia (HIT) is a serious condition affecting about 5% of patients on heparin. Promptly stopping heparin is crucial for Type II HIT, the severe immune-mediated form.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iliac Venous Stenting for Outflow Obstruction Does Not Significantly Change the Quality of Life of Patients With Severe Chronic Venous Insufficiency.

Journal of vascular surgery. Venous and lymphatic disorders·2020
Same author

Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia.

Gene therapy·2016
Same author

Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia.

Gene therapy·2015
Same author

Exclusion of accessory renal arteries during endovascular repair of abdominal aortic aneurysms.

Journal of vascular surgery·2001
Same author

Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia.

Journal of vascular surgery·2001
Same author

Adenovirus-mediated transfer and expression of beta-gal in injured hippocampus after traumatic brain injury in mice.

Journal of neurotrauma·2001

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Heparin-induced thrombocytopenia (HIT) is a procoagulant disorder with significant clinical implications.
  • It affects approximately 5% of patients undergoing heparin therapy.
  • HIT presents in two distinct types: Type I (non-immune, mild) and Type II (immune-mediated, severe).

Purpose of the Study:

  • To differentiate between Type I and Type II HIT.
  • To outline the clinical presentation and pathophysiological mechanisms of HIT.
  • To emphasize the importance of early detection and management of HIT.

Main Methods:

  • Clinical presentation analysis.
  • Pathophysiological mechanism investigation.
  • Distinguishing between immune-mediated and non-immune-mediated thrombocytopenia.

Main Results:

  • Type I HIT is an early, mild, non-immune-mediated form requiring no specific therapy.
  • Type II HIT is a delayed, severe, immune-mediated form associated with Heparin-induced with Thrombocytopenia and Thrombosis (HITT).
  • Thrombocytopenia in Type II HIT typically resolves within days to a week after heparin withdrawal.

Conclusions:

  • Heparin therapy must be discontinued upon suspicion or diagnosis of HIT, particularly Type II.
  • Early recognition and management are vital to mitigate morbidity and mortality associated with HIT.
  • Preventive strategies focusing on minimizing patient risk are paramount.

Related Experiment Videos